3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine

Absorption
Tmax is 2 to 4 h. Steady state is reached in 2 to 5 days.

Distribution
More than 90% is protein bound. Lipid soluble.

Metabolism
Significant first pass effect. Metabolism occurs in liver. Active metabolite is desipramine.

Elimination
The t½ is 11 to 25 h.

Peak
2 to 4 weeks.

Carbamazepine
Carbamazepine levels may increase; imipramine levels may decrease.

Cimetidine, fluoxetine
May cause increased imipramine blood levels and effects.

Clonidine
May result in hypertensive crisis.

CNS depressants
Depressant effects may be additive.

Dicumarol
Anticoagulant actions may increase.

Guanethidine
Hypotensive action may be inhibited.

MAO inhibitors
May cause hyperpyretic crises, severe convulsions, and death when given with imipramine.

Sympathomimetics
Pressor response may be decreased by indirect-acting sympathomimetics and increased by direct-acting ones.